Még nem toboroz
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Contact: Alexion Pharmaceuticals, Inc., Sponsor
Toboroz
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
NCT07619131· 3. fázis· AstraZeneca· Forrás
Toboroz
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
NCT07681596· 1/2. fázis· AstraZeneca· Forrás
Toboroz
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658· 2. fázis· AstraZeneca· Forrás
Toboroz
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657· 3. fázis· AstraZeneca· Forrás
Toboroz
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
NCT07129993· 2/3. fázis· Daiichi Sankyo· Forrás
Még nem toboroz
LTFU for All Cell and Gene Therapy Studies
NCT06194461· AstraZeneca· Forrás
Toboroz
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719· 3. fázis· Arcus Biosciences, Inc.· Forrás
Contact: Medical Director
Toboroz
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338· 2. fázis· AstraZeneca· Forrás
Toboroz
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
NCT07073547· 1. fázis· AstraZeneca· Forrás
Toboroz
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
NCT06897930· 1/2. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
NCT06878261· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305· 3. fázis· AstraZeneca· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT06830629· 2. fázis· Maze Therapeutics· Forrás
Contact: Maze Therapeutics
Fut, nem toboroz
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927· 3. fázis· Arcus Biosciences, Inc.· Forrás
Toboroz
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449· 3. fázis· AstraZeneca· Forrás
Toboroz
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665· 3. fázis· AstraZeneca· Forrás
Toboroz
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NCT06008093· 2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of AZD0754 in Participants With Metastatic Prostate Cancer
NCT06267729· 1/2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
NCT06040099· 2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Toboroz
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118· 1/2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884· 1/2. fázis· AstraZeneca· Forrás
Toboroz
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945· 1/2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728· 3. fázis· AstraZeneca· Forrás
Toboroz
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861· 3. fázis· DalCor Pharmaceuticals· Forrás
Contact: David Kallend, MBBS
Toboroz
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589· 3. fázis· AstraZeneca· Forrás
Toboroz
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
NCT05850234· 1/2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT05536141· 1. fázis· Arcus Biosciences, Inc.· Forrás
Contact: Medical Director
Fut, nem toboroz
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133· 3. fázis· AstraZeneca· Forrás
Showing 50 of 61.